collection
MENU ▼
Read by QxMD icon Read
search

MMCBreast Collection

shared collection
321 papers 100 to 500 followers
https://www.readbyqxmd.com/read/29214416/breast-conserving-surgery-following-neoadjuvant-therapy-a-systematic-review-on-surgical-outcomes
#1
REVIEW
José H Volders, Vera L Negenborn, Pauline E Spronk, Nicole M A Krekel, Linda J Schoonmade, Sybren Meijer, Isabel T Rubio, M Petrousjka van den Tol
PURPOSE: Neoadjuvant chemotherapy (NACT) is increasingly used in breast cancer treatment. One of the main goals of NACT is to reduce the extent of local surgery of the breast and axilla. The aim of this study was to determine surgical outcomes for patients receiving breast-conserving therapy (BCT) after NACT, including margin status plus secondary surgeries, excision volumes, and cosmetic outcomes. METHODS: A systematic review was performed in accordance with PRISMA principles...
December 6, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29211674/mechanisms-of-resistance-to-neoadjuvant-chemotherapy-in-breast-cancer
#2
Angela DeMichele, Douglas Yee, Laura Esserman
New England Journal of Medicine, Volume 377, Issue 23, Page 2287-2289, December 2017.
December 7, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29211679/contemporary-hormonal-contraception-and-the-risk-of-breast-cancer
#3
Lina S Mørch, Charlotte W Skovlund, Philip C Hannaford, Lisa Iversen, Shona Fielding, Øjvind Lidegaard
BACKGROUND: Little is known about whether contemporary hormonal contraception is associated with an increased risk of breast cancer. METHODS: We assessed associations between the use of hormonal contraception and the risk of invasive breast cancer in a nationwide prospective cohort study involving all women in Denmark between 15 and 49 years of age who had not had cancer or venous thromboembolism and who had not received treatment for infertility. Nationwide registries provided individually updated information about the use of hormonal contraception, breast-cancer diagnoses, and potential confounders...
December 7, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29208760/effectiveness-of-and-overdiagnosis-from-mammography-screening-in-the-netherlands-population-based-study
#4
Philippe Autier, Magali Boniol, Alice Koechlin, Cécile Pizot, Mathieu Boniol
Objective To analyse stage specific incidence of breast cancer in the Netherlands where women have been invited to biennial mammography screening since 1989 (ages 50-69) and 1997 (ages 70-75), and to assess changes in breast cancer mortality and quantified overdiagnosis.Design Population based study.Setting Mammography screening programme, the Netherlands.Participants Dutch women of all ages, 1989 to 2012.Main outcome measures Stage specific age adjusted incidence of breast cancer from 1989 to 2012. The extra numbers of in situ and stage 1 breast tumours associated with screening were estimated by comparing rates in women aged 50-74 with those in age groups not invited to screening...
December 5, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29132566/are-there-alternative-strategies-for-the-local-management-of-ductal-carcinoma-in-situ
#5
REVIEW
Kelly J Rosso, Anna Weiss, Alastair M Thompson
The management of ductal carcinoma in situ (DCIS) has traditionally followed the evidence base for invasive breast cancer using surgery, radiation therapy, and drug therapy to remove the DCIS from the breast and reduce the risk of recurrence for both DCIS and invasive breast cancer. Because of concerns regarding the overtreatment of DCIS, randomized controlled trials have been established to test the outcomes (invasive breast cancer outcomes and patient-reported outcome measures) of active surveillance compared with guideline-concordant care for low-risk (for progression) DCIS...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29174281/controversies-and-recommendations-regarding-sentinel-lymph-node-biopsy-in-primary-breast-cancer-a%C3%A2-comprehensive-review-of-current-data
#6
REVIEW
Petros Charalampoudis, Christos Markopoulos, Tibor Kovacs
In primary breast cancer, sentinel lymph node biopsy has been established as the gold standard for regional axillary staging. A robust body of randomized data support its accuracy and safety in patients with early, clinically node negative disease. However, the role of SLNB remains debatable in various patient subgroups, and recent advances in histopathology, dedicated axillary ultrasound imaging and chemotherapy regimens, put its role under a new perspective. Herein, we review the current literature data on the indications for SLNB and discuss the challenges in management germane to special patient subgroups and patterns of disease...
November 13, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29172171/trastuzumab-for-metastatic-breast-cancer-real-world-outcomes-from-an-australian-whole-of-population-cohort-2001-2016
#7
Benjamin Daniels, Belinda E Kiely, Sarah J Lord, Nehmat Houssami, Christine Y Lu, Robyn L Ward, Sallie-Anne Pearson
PURPOSE: Outcomes for patients treated in clinical trials may not reflect the experience in routine clinical care. We aim to describe the real-world treatment patterns and overall survival (OS) for women receiving trastuzumab for metastatic breast cancer (MBC). METHODS: Retrospective, whole-of-population cohort study using demographic, dispensing, and medical services data for women in the Herceptin Program for HER2+MBC. We estimated time on trastuzumab and OS from first dispensing of trastuzumab for MBC and rates of cardiac monitoring prior to and during treatment...
November 21, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29168099/benchmarking-the-american-society-of-breast-surgeon-member-performance-for-more-than-a-million-quality-measure-patient-encounters
#8
Jeffrey Landercasper, Oluwadamilola M Fayanju, Lisa Bailey, Tiffany S Berry, Andrew J Borgert, Robert Buras, Steven L Chen, Amy C Degnim, Joshua Froman, Jennifer Gass, Caprice Greenberg, Starr Koslow Mautner, Helen Krontiras, Luis D Ramirez, Michelle Sowden, Barbara Wexelman, Lee Wilke, Roshni Rao
BACKGROUND: Nine breast cancer quality measures (QM) were selected by the American Society of Breast Surgeons (ASBrS) for the Centers for Medicare and Medicaid Services (CMS) Quality Payment Programs (QPP) and other performance improvement programs. We report member performance. STUDY DESIGN: Surgeons entered QM data into an electronic registry. For each QM, aggregate "performance met" (PM) was reported (median, range and percentiles) and benchmarks (target goals) were calculated by CMS methodology, specifically, the Achievable Benchmark of Care™ (ABC) method...
November 22, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29159748/molecular-genomic-testing-for-breast-cancer-utility-for-surgeons
#9
REVIEW
Oluwadamilola M Fayanju, Ko Un Park, Anthony Lucci
Molecular genomic testing provides clinicians with both prognostic and (sometimes) predictive information that can help individualize treatment and decrease the risk of over- or under-treatment. We review the genomic tests that are currently available for clinical use in management of breast cancer, discuss ongoing research related to validating and expanding their utility in different patient populations, and explain why it is important for surgeons to know how to incorporate these tools into their clinical practice in order to individualize patient treatment, reduce unnecessary morbidity, and, accordingly, improve outcomes...
November 20, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29143220/validation-of-the-8th-ajcc-prognostic-staging-system-for-breast-cancer-in-a-population-based-setting
#10
Omar Abdel-Rahman
OBJECTIVES: To validate the newly proposed American Joint Committee on Cancer (AJCC) prognostic staging system for breast cancer. METHODS: Surveillance, epidemiology, and end results (SEER) database (2010-2014) was accessed. Cumulative incidence function was conducted (through assessment of sub-distribution hazard) according to both anatomical and prognostic stages. Likewise, Cox cause-specific hazard ratio with pairwise hazard ratio comparisons were also assessed for both anatomical and prognostic stages...
November 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29128898/21-gene-recurrence-score-for-prognosis-and-prediction-of-taxane-benefit-after-adjuvant-chemotherapy-plus-endocrine-therapy-results-from-nsabp-b-28-nrg-oncology
#11
Eleftherios P Mamounas, Gong Tang, Soonmyung Paik, Frederick L Baehner, Qing Liu, Jong-Hyeon Jeong, S Rim Kim, Steven M Butler, Farid Jamshidian, Diana B Cherbavaz, Amy P Sing, Steven Shak, Thomas B Julian, Barry C Lembersky, D Lawrence Wickerham, Joseph P Costantino, Norman Wolmark
BACKGROUND: The 21-gene recurrence score (RS) predicts outcome and benefit from adjuvant chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the NSABP B-28 study, we evaluated the 21-gene RS for its prognostic impact and its ability to predict benefit from paclitaxel (P) in node-positive, estrogen receptor-positive (ER+) breast cancer patients treated with adjuvant chemotherapy plus tamoxifen. METHODS: The B-28 trial compared doxorubicin/cyclophosphamide (AC) with AC followed by P in 3060 patients...
November 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29127538/the-shifting-paradigm-for-breast-cancer-surgery-in-patients-undergoing-neoadjuvant-chemotherapy
#12
Olga Kantor, Gaurav Ajmani, Chi-Hsiung Wang, Avisek Datta, Katharine Yao
INTRODUCTION: Surgical therapy for newly diagnosed breast cancer has changed over the past decade, but these trends have not been well documented in patients undergoing neoadjuvant therapy (NAC). METHODS: In a retrospective cohort study of the National Cancer Database (NCDB), we selected 285,514 women with clinical stage I-III breast cancer who underwent NAC or adjuvant therapy (AC) from 2006 to 2014. Breast-conserving surgery (BCS), unilateral mastectomy (UM), and bilateral mastectomy (BM) rates were compared between patients undergoing NAC and AC...
November 10, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29116466/breast-cancer-related-paraneoplastic-neurologic-disease
#13
Brittany L Murphy, Nicholas L Zalewski, Amy C Degnim, Andrew McKeon, Eoin P Flanagan, Sean J Pittock, Elizabeth B Habermann
PURPOSE: Paraneoplastic neurologic disease (PND) is an aberrant immune-mediated response against the nervous system triggered by malignancy. Given the rarity, a paucity of data describing breast cancer-related PND (BC-PND) exists; we sought to further examine this specific patient population. METHODS: We retrospectively identified patients at our institution from 1997 to 2016 with BC-PND. Retrospective review with a descriptive analysis determined factors associated with PND and BC, which were compared to national breast cancer median of age (61 years) and average stage at diagnosis (60% local disease)...
November 7, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29117498/20-year-risks-of-breast-cancer-recurrence-after-stopping-endocrine-therapy-at-5-years
#14
Hongchao Pan, Richard Gray, Jeremy Braybrooke, Christina Davies, Carolyn Taylor, Paul McGale, Richard Peto, Kathleen I Pritchard, Jonas Bergh, Mitch Dowsett, Daniel F Hayes
BACKGROUND: The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment. METHODS: In this meta-analysis of the results of 88 trials involving 62,923 women with ER-positive breast cancer who were disease-free after 5 years of scheduled endocrine therapy, we used Kaplan-Meier and Cox regression analyses, stratified according to trial and treatment, to assess the associations of tumor diameter and nodal status (TN), tumor grade, and other factors with patients' outcomes during the period from 5 to 20 years...
November 9, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29100726/expanding-implementation-of-acosog-z0011-in-surgeon-practice
#15
Anna Weiss, Elizabeth A Mittendorf, Sarah M DeSnyder, Rosa F Hwang, Vivian Bea, Isabelle Bedrosian, Karen Hoffman, Beatriz Adrade, Aysegul A Sahin, Henry M Kuerer, Kelly K Hunt, Abigail S Caudle
BACKGROUND: After publication of American College of Surgeons Oncology Group (ACOSOG) Z0011, surgeons at our institution limited axillary surgery to sentinel lymph node dissection (SLND) in 76% of patients meeting trial eligibility criteria. Our study objective was to assess incorporation of the trial data into practice 5 years later. PATIENTS AND METHODS: Patients with clinical T1-2, N0 invasive breast cancer undergoing breast conserving surgery were included. Comparisons were made between patients who underwent axillary lymph node dissection (ALND) and those that had no further surgery...
October 13, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29102781/outcomes-of-immediate-versus-delayed-breast-reconstruction-results-of-a-multicenter-prospective-study
#16
Alfred P Yoon, Ji Qi, David L Brown, Hyungjin M Kim, Jennifer B Hamill, Jessica Erdmann-Sager, Andrea L Pusic, Edwin G Wilkins
BACKGROUND: Previous studies suggest that immediate reconstruction following mastectomy produces superior results over delayed procedures. However, for medical or oncological reasons, some patients may be poor candidates for immediate reconstruction. We compared complications and patient-reported outcomes between immediate and delayed breast reconstructions in a prospective, multicenter study. METHODS: 1957 patients (1806 immediate, 151 delayed) met eligibility criteria...
November 2, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29092024/characterization-of-male-breast-cancer-results-of-the-eortc-10085-tbcrc-big-nabcg-international-male-breast-cancer-program
#17
F Cardoso, J M S Bartlett, L Slaets, C H M van Deurzen, E van Leeuwen-Stok, P Porter, B Linderholm, I Hedenfalk, C Schröder, J Martens, J Bayani, C van Asperen, M Murray, C Hudis, L Middleton, J Vermeij, K Punie, J Fraser, M Nowaczyk, I T Rubio, S Aebi, C Kelly, K J Ruddy, E Winer, C Nilsson, L Dal Lago, L Korde, K Benstead, O Bogler, T Goulioti, A Peric, S Litière, K C Aalders, C Poncet, K Tryfonidis, S H Giordano
Background: Male breast cancer (BC) is rare, managed by extrapolation from female BC. The International Male BC Program aims to better characterize and manage this disease. We report the results of part 1, a retrospective-joint-analysis of cases diagnosed during a 20-year-period. Methods: Patients with follow-up and tumor samples, treated between 1990-2010, in 93 centers/nine countries. Samples were centrally analyzed in three labs (UK, NL, US). Results: Of 1822 patients enrolled, 1483 were analyzed; 63...
October 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29079937/clinical-risk-score-to-predict-likelihood-of-recurrence-after-ductal-carcinoma-in-situ-treated-with-breast-conserving-surgery
#18
Rinaa S Punglia, Wei Jiang, Stuart R Lipsitz, Melissa E Hughes, Stuart J Schnitt, Michael J Hassett, Larissa Nekhlyudov, Ninah Achacoso, Stephen Edge, Sara H Javid, Joyce C Niland, Richard L Theriault, Yu-Ning Wong, Laurel A Habel
PURPOSE: A majority of women with ductal carcinoma in situ (DCIS) receive breast-conserving surgery (BCS) but then face a risk of ipsilateral breast tumor recurrence (IBTR) which can be either recurrence of DCIS or invasive breast cancer. We developed a score to provide individualized information about IBTR risk to guide treatment decisions. METHODS: Data from 2762 patients treated with BCS for DCIS at centers within the National Comprehensive Cancer Network (NCCN) were used to identify statistically significant non-treatment-related predictors for 5-year IBTR...
October 28, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29070982/advanced-imaging-for-precision-medicine-in-breast-cancer-from-morphology-to-function
#19
EDITORIAL
Katja Pinker
No abstract text is available yet for this article.
September 2017: Breast Care
https://www.readbyqxmd.com/read/29049466/breast-implant-associated-anaplastic-large-cell-lymphoma-a-systematic-review
#20
Ashley N Leberfinger, Brittany J Behar, Nicole C Williams, Kevin L Rakszawski, John D Potochny, Donald R Mackay, Dino J Ravnic
Importance: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare peripheral T-cell lymphoma, is increasing in incidence. However, many practitioners who treat patients with breast cancer are not aware of this disease. Objectives: To assess how BIA-ALCL develops, its risk factors, diagnosis, and subsequent treatment and to disseminate information about this entity to the medical field. Evidence Review: A literature review was performed in an academic medical setting...
October 18, 2017: JAMA Surgery
label_collection
label_collection
6331
1
2
2017-10-26 13:19:10
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"